Gene Section Review

Total Page:16

File Type:pdf, Size:1020Kb

Gene Section Review Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Gene Section Review GLS2 (Glutaminase 2) José A Campos-Sandoval, Mercedes Martín-Rufián, Javier Márquez Department of Molecular Biology and Biochemistry, Faculty of Sciences, Campus de Teatinos, University of Málaga, 29071 Málaga, Spain, and Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Málaga, Spain; [email protected], [email protected], [email protected] Published in Atlas Database: April 2019 Online updated version : http://AtlasGeneticsOncology.org/Genes/GLS2ID46328ch12q13.html Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/70607/04-2019-GLS2ID46328ch12q13.pdf DOI: 10.4267/2042/70607 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2019 Atlas of Genetics and Cytogenetics in Oncology and Haematology GLS, regulated by oncogenes and associated to Abstract tumorigenesis. However, recent findings indicate Mammalian glutaminases are encoded by two that GLS2 is upregulated in some types of cancer paralogous genes, Gls and Gls2, presumably derived (NMYC-amplified neuroblastoma, cervical, colon by gene duplication of a common ancestor. Each and lung cancers) and this upregulation gene codes for two different isoforms. The two paradoxically correlates with poor clinical outcomes. transcripts of Gls2, named GAB and LGA, arise Keywords through a surrogate promoter usage mechanism. In Glutaminase; Neuroblastoma; Cervical cancer; certain types of malignancies, such as glioblastoma Colon cancer; Lung cancer and liver cancers, expression of GLS2 gene is repressed by promoter hypermethylation, which could contribute to the malignant process. The Identity finding that ectopic expression of GLS2 could Other names: GA, PAG, GAB, LGA, hLGA inhibit proliferation of these tumors led to the hypothesis that this isoenzyme, a transcriptional HGNC (Hugo): GLS2 target of TP53, might play a role as tumor Location: 12q13.3 suppressor, in opposition to Figure 1. Genomic structure of human glutaminase GLS2 gene and alternative transcripts GAB and LGA. Introns are depicted as solid light blue lines and exons as numbered dark blue boxes. Dashed red or dotted black lines indicate the exons involved in the generation of GAB and LGA transcripts, respectively (Campos-Sandoval et al., 2015). DNA/RNA Atlas Genet Cytogenet Oncol Haematol. 2019; 23(11) 326 GLS2 (Glutaminase 2) Campos-Sandoval JA et al. Description differentiation and in cancer cells exposed to oxidative stress (Giacobbe et al., 2013), respectively. Human GLS2 gene is located on chromosome 12 The GLS2 downregulation observed in liver and (Aledo et al., 2000). It is composed of 18 exons and colon cancer cell lines and in hepatocellular spans approximately 18 kb (Pérez-Gómez et al., carcinoma has been attributed to its promoter 2003). The gene resides on the minus strand. It starts hypermethylation, a mechanism that has been at 56470944 and ends at 56488414 from pter (NCBI, proposed as a marker to identify novel tumor Gene ID 27165). suppressor genes. Chemical demethylation treatment Transcription increased the GLS2 mRNA levels in these cells Two GLS2 transcripts coding for functional proteins (Zhang et al., 2013; Liu et al., 2014). This have been described: a long canonical one mechanism is also responsible for the GLS2 containing all 18 exons (GAB), cloned from a human silencing detected in highly malignant breast cancer cell line (Gómez-Fabre et al., 2000) glioblastomas, and occurs regardless of their TP53 and a short variant (LGA), first characterized in rat status (Szeliga et al., 2016). Other factors that liver (Smith and Watford, 1990; Chung-Bok et al., regulate GLS2 expression are the MYCN 1997) and lacking the first exon (Martèn-Rufián et oncoprotein (v-myc avian myelocytomatosis viral al., 2012). LGA transcript arises by a combination of oncogene neuroblastoma derived homolog, encoded two mechanisms of transcriptional regulation: by MYCN gene) and the NR5A2 (nuclear receptor alternative transcription initiation and alternative subfamily 5 group A member 2), also known as promoter. Its transcription start site is located at 3- LRH-1 (liver receptor homolog 1). MYCN, an end of the first intron of GLS2 gene. Other non- essential MYC family member, directly activates coding transcripts, containing premature stop GLS2 transcription in MYCN-amplified codons, have been isolated (Martèn-Rufián et al., neuroblastoma cells. Depletion of MYCN 2012). expression by short hairpin RNA caused a The molecular basis for GLS2 regulation is now pronounced decrease in GLS2 (but not GLS) levels starting to be uncovered. GLS2 has been identified in these cells. Conversely, inhibition of TP53 had no as a transcriptional target of tumor suppressor TP53 effect on GLS2 induction (Xiao et al., 2015). In that mediates its new revealed functions in tumor hepatoma cells, GLS2 is subjected to direct metabolism and antioxidant defense, under both transcriptional regulation by NR5A2. Silencing of non-stressed and stressed conditions. This tumor NR5A2 mediated by small interfering RNA reduced suppressor directly associates with response GLS2 transcript and protein levels (Xu et al., 2016). elements in the GLS2 promoter (Hu et al., 2010; Long non-coding RNA (lncRNA) and microRNAs Suzuki et al., 2010). Cells with heightened GLS2 (miRNAs) are also implicated in GLS2 regulation. levels showed increased production of glutamate and The lncRNA urothelial carcinoma-associated 1 ( alpha-ketoglutarate, which resulted in enhanced UCA1) regulates GLS2 expression levels through oxydative phosphorylation, higher GSH/GSSG interfering with MIR16-1, which binds to the 3'-UTR ratios and decreased reactive oxygen species (ROS) (untranslated region) of GLS2 mRNA (Li et al., levels, which provided protection against ROS 2016). induced apoptosis (Hu et al., 2010; Suzuki et al., 2010). Two other transcription factors belonging to Pseudogene the TP53 family, TP73 and TP63, also drive the At least one pseudogene has been reported for GLS2 expression of GLS2 during neuronal differentiation (GenBank: AF110329.1). of neuroblastoma cells after induction with retinoic acid (Velletri et al., 2013) and during epidermal Figure 2. Schematic diagram of GLS2 isoforms showing the localization of predicted domains and motifs by sequence analysis (Márquez et al., 2016). Protein Atlas Genet Cytogenet Oncol Haematol. 2019; 23(11) 327 GLS2 (Glutaminase 2) Campos-Sandoval JA et al. Description Studies on processing and molecular structure of native GLS2 protein are lacking. An apparent Purification: the first attempts to purify liver-type subunit molecular mass of 57-58 kDa for the rat liver glutaminase from rat liver only yielded partial isoform was determined by denaturing gel purifications: 15-fold (Huang and Knox, 1976) and electrophoresis of purified protein (Heini et al., 60-fold (Patel and McGivan, 1984). Unlike kidney- 1987; Smith and Watford, 1988). Sequencing by type glutaminase (KGA), the liver isoenzyme does Edman degradation of the mature form of human not polymerize in the presence of phosphate-borate GAB expressed in baculovirus system showed buffer (Huang and Knox, 1976). This different cleavage between amino acids 38-39 and 39-40 of behaviour, together with its greater instability in the deduced protein sequence. These cleavages are tissue homogenates and diluted preparations, made consistent with known substrate sites for the this isoenzyme more difficult to purify than KGA. In mitochondrial processing peptidase (MPP), having fact, its purification to near homogeneity was not an Arg residue at position -2 or -3. Nevertheless, achieved until almost two decades later than KGA processing in baculovirus system may somehow purification. Heini et al. (1987) purified rat LGA differ from the native processing in mammals 400-fold, while Smith and Watford (1988) reported (Campos-Sandoval et al., 2007). The molecular mass a 600-fold purification, with specific activities of 30- (Mr) of native GLS2 has not been determined 50 μmol/min per mg protein. Human GAB accurately. Smith and Watford (1988) reported an isoenzyme has been expressed as a recombinant Mr of ≥ 300000 from HPLC gel filtration but protein in baculovirus system and purified by obtained a value of 162000 by sucrose gradient affinity chromatography with a specific activity of centrifugation, regardless of phosphate 18 μmol/min per mg protein (Campos-Sandoval et concentration (5 or 100 mM). al., 2007). Kinetic properties: the distinct kinetic behavior of Structure: human GAB transcript (ORF: 1809 nt) mammalian kydney-type and liver-type isoenzymes codes a 602-residues protein, with a predicted was first noted by Krebs (1935). In contrast with molecular mass of 66.3 kDa. Human LGA transcript kydney-type isoenzyme, the rat liver-type (ORF: 1698 nt) codes a 565-residues protein, with a glutaminase showed a lower dependence on the predicted molecular mass of 62.5 kDa. The precursor activator inorganic phosphate (Pi), lower affinity for of human LGA isoform lacks the first 61 residues of the substrate glutamine, lack of inhibition by GAB precursor (coded by exon 1), but it displays an glutamate (up to 50 mM) and a requirement for additional extension of 24 novel residues at the N- ammonia as an obligatory activator (Verhoeven et terminus coded by an alternative first exon. This al., 1983; Patel and McGivan, 1984; Smith and extension and the first six amino acids coded by exon Watford, 1988). The
Recommended publications
  • PARSANA-DISSERTATION-2020.Pdf
    DECIPHERING TRANSCRIPTIONAL PATTERNS OF GENE REGULATION: A COMPUTATIONAL APPROACH by Princy Parsana A dissertation submitted to The Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland July, 2020 © 2020 Princy Parsana All rights reserved Abstract With rapid advancements in sequencing technology, we now have the ability to sequence the entire human genome, and to quantify expression of tens of thousands of genes from hundreds of individuals. This provides an extraordinary opportunity to learn phenotype relevant genomic patterns that can improve our understanding of molecular and cellular processes underlying a trait. The high dimensional nature of genomic data presents a range of computational and statistical challenges. This dissertation presents a compilation of projects that were driven by the motivation to efficiently capture gene regulatory patterns in the human transcriptome, while addressing statistical and computational challenges that accompany this data. We attempt to address two major difficulties in this domain: a) artifacts and noise in transcriptomic data, andb) limited statistical power. First, we present our work on investigating the effect of artifactual variation in gene expression data and its impact on trans-eQTL discovery. Here we performed an in-depth analysis of diverse pre-recorded covariates and latent confounders to understand their contribution to heterogeneity in gene expression measurements. Next, we discovered 673 trans-eQTLs across 16 human tissues using v6 data from the Genotype Tissue Expression (GTEx) project. Finally, we characterized two trait-associated trans-eQTLs; one in Skeletal Muscle and another in Thyroid. Second, we present a principal component based residualization method to correct gene expression measurements prior to reconstruction of co-expression networks.
    [Show full text]
  • Glutaminase 2 Induces Interleukin-2 Production in CD4+ T Cells by Supporting Antioxidant Defense
    Glutaminase 2 Induces Interleukin-2 Production in CD4+ T Cells by Supporting Antioxidant Defense The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Orite, Seo Yeon Kim. 2019. Glutaminase 2 Induces Interleukin-2 Production in CD4+ T Cells by Supporting Antioxidant Defense. Master's thesis, Harvard Medical School. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:42057407 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use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
    [Show full text]
  • Identification the Ferroptosis-Related Gene Signature in Patients with Esophageal Adenocarcinoma
    Zhu et al. Cancer Cell Int (2021) 21:124 https://doi.org/10.1186/s12935-021-01821-2 Cancer Cell International PRIMARY RESEARCH Open Access Identifcation the ferroptosis-related gene signature in patients with esophageal adenocarcinoma Lei Zhu1,2,3†, Fugui Yang1,2†, Lingwei Wang1,2, Lin Dong1,2, Zhiyuan Huang1,2, Guangxue Wang2, Guohan Chen1* and Qinchuan Li1,2* Abstract Background: Ferroptosis is a recently recognized non-apoptotic cell death that is distinct from the apoptosis, necroptosis and pyroptosis. Considerable studies have demonstrated ferroptosis is involved in the biological process of various cancers. However, the role of ferroptosis in esophageal adenocarcinoma (EAC) remains unclear. This study aims to explore the ferroptosis-related genes (FRG) expression profles and their prognostic values in EAC. Methods: The FRG data and clinical information were downloaded from The Cancer Genome Atlas (TCGA) database. Univariate and multivariate cox regressions were used to identify the prognostic FRG, and the predictive ROC model was established using the independent risk factors. GO and KEGG enrichment analyses were performed to investi- gate the bioinformatics functions of signifcantly diferent genes (SDG) of ferroptosis. Additionally, the correlations of ferroptosis and immune cells were assessed through the single-sample gene set enrichment analysis (ssGSEA) and TIMER database. Finally, SDG were verifed in clinical EAC specimens and normal esophageal mucosal tissues. Results: Twenty-eight signifcantly diferent FRG were screened from 78 EAC and 9 normal tissues. Enrichment analyses showed these SDG were mainly related to the iron-related pathways and metabolisms of ferroptosis. Gene network demonstrated the TP53, G6PD, NFE2L2 and PTGS2 were the hub genes in the biology of ferroptosis.
    [Show full text]
  • The Fundamental Role of the P53 Pathway in Tumor Metabolism and Its Implication in Tumor Therapy
    Author Manuscript Published OnlineFirst on February 3, 2012; DOI: 10.1158/1078-0432.CCR-11-3040 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. The fundamental role of the p53 pathway in tumor metabolism and its implication in tumor therapy Lan Shen1,Xiang Sun2,Zhenhong Fu3,Guodong Yang1,Jianying Li1,and Libo Yao1,* 1 Department of Biochemistry and Molecular Biology, The State Key Laboratory of Cancer Biology, The Fourth Military Medical University, Xi’an 710032, The People’s Republic of China 2 Department of Prosthodontics, School of Stomatology, The Fourth Military Medical University, Xi’an 710032, The People’s Republic of China 3 Department of Cardiology, The General Hospital of the People’s Liberation Army, Beijing 100853, The People’s Republic of China L. Shen, X. Sun and Z-H. Fu contributed equally to this work. * Corresponding author: Department of Biochemistry and Molecular Biology, The State Key Laboratory of Cancer Biology, The Fourth Military Medical University, Xi’an 710032, The People’s Republic of China. Phone: 86-29-84774513; Fax: 86-29-84773947; E-mail: [email protected]. Statement of translational relevance The tumor suppressor p53 is one of the most highly studied in the field of cancer research due to its functions on tumor cell survival and apoptosis. However, tumor metabolic reprogramming fuels cancer cell malignant growth and proliferation. In this review, we systematically document the mechanisms of p53 in tumor metabolism regulation. On this basis, we analyzed the therapeutic strategy whereby p53 helps to prevent tumor malignant metabolic phenotype, bioenergetic, and biosynthetic processes, and blocking the reprogramming of tumor metabolism will provide new strategies for tumor therapy.
    [Show full text]
  • Characterization of the Scavenger Cell Proteome in Mouse and Rat Liver
    Biol. Chem. 2021; 402(9): 1073–1085 Martha Paluschinski, Cheng Jun Jin, Natalia Qvartskhava, Boris Görg, Marianne Wammers, Judith Lang, Karl Lang, Gereon Poschmann, Kai Stühler and Dieter Häussinger* Characterization of the scavenger cell proteome in mouse and rat liver + https://doi.org/10.1515/hsz-2021-0123 The data suggest that the population of perivenous GS Received January 25, 2021; accepted July 4, 2021; scavenger cells is heterogeneous and not uniform as previ- published online July 30, 2021 ously suggested which may reflect a functional heterogeneity, possibly relevant for liver regeneration. Abstract: The structural-functional organization of ammonia and glutamine metabolism in the liver acinus involves highly Keywords: glutaminase; glutamine synthetase; liver specialized hepatocyte subpopulations like glutamine syn- zonation; proteomics; scavenger cells. thetase (GS) expressing perivenous hepatocytes (scavenger cells). However, this cell population has not yet been char- acterized extensively regarding expression of other genes and Introduction potential subpopulations. This was investigated in the present study by proteome profiling of periportal GS-negative and There is a sophisticated structural-functional organization in perivenous GS-expressing hepatocytes from mouse and rat. the liver acinus with regard to ammonium and glutamine Apart from established markers of GS+ hepatocytes such as metabolism (Frieg et al. 2021; Gebhardt and Mecke 1983; glutamate/aspartate transporter II (GLT1) or ammonium Häussinger 1983, 1990). Periportal hepatocytes express en- transporter Rh type B (RhBG), we identified novel scavenger zymes required for urea synthesis such as the rate-controlling cell-specific proteins like basal transcription factor 3 (BTF3) enzyme carbamoylphosphate synthetase 1 (CPS1) and liver- and heat-shock protein 25 (HSP25).
    [Show full text]
  • (KGA) and Its Regulation by Raf-Mek-Erk Signaling in Cancer Cell Metabolism
    Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism K. Thangavelua,1, Catherine Qiurong Pana,b,1, Tobias Karlbergc, Ganapathy Balajid, Mahesh Uttamchandania,d,e, Valiyaveettil Sureshd, Herwig Schülerc, Boon Chuan Lowa,b,2, and J. Sivaramana,2 Departments of aBiological Sciences and dChemistry, National University of Singapore, Singapore 117543; bMechanobiology Institute Singapore, National University of Singapore, Singapore 117411; cStructural Genomics Consortium, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm SE-17177, Sweden; and eDefence Medical and Environmental Research Institute, DSO National Laboratories, Singapore 117510 Edited by John Kuriyan, University of California, Berkeley, CA, and approved March 22, 2012 (received for review October 11, 2011) Besides thriving on altered glucose metabolism, cancer cells un- a substrate for the ubiquitin ligase anaphase-promoting complex/ dergo glutaminolysis to meet their energy demands. As the first cyclosome (APC/C)-Cdh1, linking glutaminolysis to cell cycle enzyme in catalyzing glutaminolysis, human kidney-type glutamin- progression (12). In comparison, function and regulation of LGA is ase isoform (KGA) is becoming an attractive target for small not well studied, although it was recently shown to be linked to p53 pathway (13, 14). Although intense efforts are being made to de- molecules such as BPTES [bis-2-(5 phenylacetamido-1, 2, 4-thiadia- fi fi velop a speci c KGA inhibitor such as BPTES [bis-2-(5-phenyl- zol-2-yl) ethyl sul de], although the regulatory mechanism of KGA acetamido-1, 2, 4-thiadiazol-2-yl) ethyl sulfide] (15), its mechanism remains unknown.
    [Show full text]
  • Transcription Factor Gata3 Expression Is Induced by Gls2 Overexpression in a Glioblastoma Cell Line but Is Gls2-Independent in Patient-Derived Glioblastoma
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 2017, 68, 2, 209-214 www.jpp.krakow.pl E. MAJEWSKA1, R. ROLA2, M. BARCZEWSKA3, J. MARQUEZ4, J. ALBRECHT1, M. SZELIGA1 TRANSCRIPTION FACTOR GATA3 EXPRESSION IS INDUCED BY GLS2 OVEREXPRESSION IN A GLIOBLASTOMA CELL LINE BUT IS GLS2-INDEPENDENT IN PATIENT-DERIVED GLIOBLASTOMA 1Department of Neurotoxicology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland; 2Department of Neurosurgery and Paediatric Neurosurgery, Medical University of Lublin, Lublin, Poland; 3Department of Neurosurgery, Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, Poland; 4Department of Molecular Biology and Biochemistry, Faculty of Sciences, Campus de Teatinos, University of Malaga, Malaga, Spain Phosphate-activated glutaminase (GA), a ubiquitous glutamine-metabolizing enzyme, is encoded by two genes, GLS and GLS2. In mammalian cancers, GLS isoforms are perceived as molecules promoting cell proliferation and invasion, whereas the role of GLS2 isoforms seems to be more complex and cell type-specific. Previous studies have shown abundance of GLS and lack of GLS2 transcripts in T98G human glioblastoma (GBM) cell line and patient-derived GBM. Transfection with GAB sequence, the whole GLS2 cDNA transcript, suppressed malignant phenotype of T98G cells. Microarray analysis revealed upregulation of GATA3, the product of which has been implicated in suppressing growth of some peripheral cancers. In this study we confirmed a significant upregulation of GATA3 expression in the transfected cells both at mRNA and protein level. Considerable expression of GATA3 was also observed in GBM tissues (previously shown as not expressing GLS2), while only traces or no GATA3 was detected in (GLS2-expressing) non-tumorigenic brain samples.
    [Show full text]
  • Rabbit Anti-GLS2/FITC Conjugated Antibody
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-GLS2/FITC Conjugated antibody SL13376R-FITC Product Name: Anti-GLS2/FITC Chinese Name: FITC标记的谷氨酰胺酰胺水解酶抗体 breast cell glutaminase; Gls2; GLSL_HUMAN; glutaminase 2 (liver mitochondrial); glutaminase 2; glutaminase GA; glutaminase I; Glutaminase liver isoform; hLGA; L Alias: glutaminase; L glutamine amidohydrolase; L-glutaminase; L-glutamine amidohydrolase; LGA; mitochondrial; phosphate activated glutaminase; phosphate- dependent glutaminase. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Dog,Pig,Cow,Horse,Rabbit,Sheep, ICC=1:50-200IF=1:50-200 Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 65kDa Form: Lyophilized or Liquid Concentration: 1mg/ml immunogen: KLH conjugated synthetic peptide derived from human GLS2/LGA Lsotype: IgGwww.sunlongbiotech.com Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. background: LGA is a 602 amino acid protein that localizes to the mitochondrion and contains two ANK repeats. Expressed in brain, liver and pancreas, LGA functions as a mitochondrial Product Detail: phosphate-activated glutaminase that catalyzes the hydrolysis of glutamine to glutamate and ammonia.
    [Show full text]
  • GLS2 Mouse Monoclonal Antibody [Clone ID: OTI1C12] Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA809492 GLS2 Mouse Monoclonal Antibody [Clone ID: OTI1C12] Product data: Product Type: Primary Antibodies Clone Name: OTI1C12 Applications: IHC, WB Recommended Dilution: WB 1:2000, IHC 1:2000 Reactivity: Human, Mouse, Rat Host: Mouse Isotype: IgG2a Clonality: Monoclonal Immunogen: Full length human recombiant protein of human GLS2 (NP_037399) produced in E.coli. Formulation: PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide. Concentration: 1 mg/ml Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 66.8 kDa Gene Name: glutaminase 2 Database Link: NP_037399 Entrez Gene 192268 RatEntrez Gene 216456 MouseEntrez Gene 27165 Human Q9UI32 Background: The protein encoded by this gene is a mitochondrial phosphate-activated glutaminase that catalyzes the hydrolysis of glutamine to stoichiometric amounts of glutamate and ammonia. Originally thought to be liver-specific, this protein has been found in other tissues as well. Alternative splicing results in multiple transcript variants that encode different isoforms. [provided by RefSeq, Jul 2013] Synonyms: GA; GLS; hLGA; LGA This product is to be used for laboratory only.
    [Show full text]
  • Phosphate-Activated Glutaminase (GLS2), a P53- Inducible Regulator
    Phosphate-activated glutaminase (GLS2), a p53- SEE COMMENTARY inducible regulator of glutamine metabolism and reactive oxygen species Sawako Suzukia,b,1, Tomoaki Tanakaa,b,1, Masha V. Poyurovskyc, Hidekazu Naganoa,b, Takafumi Mayamaa,b, Shuichi Ohkubod, Maria Lokshinc, Hiroyuki Hosokawae, Toshinori Nakayamae, Yutaka Suzukif, Sumio Suganof, Eiichi Satog, Toshitaka Nagaog, Koutaro Yokotea,b, Ichiro Tatsunoa,b,2, and Carol Privesc,2 aDepartment of Clinical Cell Biology and bDivision of Endocrinology and Metabolism, Chiba University Graduate School of Medicine, Chiba-shi, Chiba 260- 8670, Japan; cDepartment of Biological Sciences, Columbia University, New York, NY 10027; dDrug Discovery and Development I, Hanno Research Institute, Taiho Pharmaceutical Co., Ltd., Hanno, Saitama 357-8527, Japan; eDepartment of Immunology, Chiba University Graduate School of Medicine, Chiba-shi, Chiba 260-8670, Japan; fDepartment of Medical Genome Sciences, Graduate School of Frontier Sciences, University of Tokyo, Kashiwa, Chiba 277-8562, Japan; and gDepartment of Anatomic Pathology, Tokyo Medical University, Shinjuku, Tokyo 160-0023, Japan Contributed by Carol Prives, March 1, 2010 (sent for review January 6, 2010) We identified a p53 target gene, phosphate-activated mitochondrial production as well as antioxidant defense through GSH synthesis. glutaminase (GLS2), a key enzyme in conversion of glutamine to glu- The two different phosphate activated GLS isoforms GLS1 (kid- tamate, and thereby a regulator of glutathione (GSH) synthesis and ney-type) and GLS2 (liver-type) in mammals are encoded by energy production. GLS2 expression is induced in response to DNA separate genes on different chromosomes (17–19). Previous data damage or oxidative stress in a p53-dependent manner, and p53 asso- have suggested that GLS1 up-regulation is associated with ciates with the GLS2 promoter.
    [Show full text]
  • Brain Glutaminases
    Article in press - uncorrected proof BioMol Concepts, Vol. 1 (2010), pp. 3–15 • Copyright ᮊ by Walter de Gruyter • Berlin • New York. DOI 10.1515/BMC.2010.006 Review Brain glutaminases Javier Ma´rquez1,*, Mercedes Martı´n-Rufia´n1, glutarate involving tricarboxylic acid cycle (TCA) reactions Juan A. Segura1, Jose´ M. Mate´s1, Jose´A. has also been reported to contribute to generation of neuro- Campos-Sandoval2 and Francisco J. Alonso1 transmitter Glu (3). In addition to the transmitter pool of Glu in excitatory synapses, a metabolic pool also exists as this 1 Departamento de Biologı´a Molecular y Bioquı´mica, amino acid is a primary metabolic fuel for brain cells (4) Laboratorio de Quı´mica de Proteı´nas, Facultad de Ciencias, and a precursor of many other important metabolites (5). In Universidad de Ma´laga, 29071 Ma´laga, Spain fact, the mitochondrial breakdown of glutamine to pyruvate, 2 Marie Curie Membrane Proteins Laboratory, Biology known as glutaminolysis, is initiated by GA and has been Department, National University of Ireland, Maynooth, Co. Kildare, Ireland largely recognized as a fundamental process for energy sup- ply in the bioenergetics of many normal and transformed cell * Corresponding author types (6). e-mail: [email protected] The concentration of free Glu in mammalian brain is high- er than in any other organ (7). Glu is found in higher con- centrations than any other free amino acid in the central Abstract nervous system (8); however, it is a nonessential amino acid that crosses the blood-brain barrier relatively poorly (9) and Glutaminase is considered as the main glutamate producer hence it must be synthesized in the brain.
    [Show full text]
  • Glutaminase 2 Is a Novel Negative Regulator of Small Gtpase Rac1 and Mediates
    1 Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates 2 p53 function in suppressing metastasis 3 4 Cen Zhang,1,4 Juan Liu,1,4 Yuhan Zhao,1 Xuetian Yue,1 Yu Zhu,1 Xiaolong Wang,1 Hao Wu1, 5 Felix Blanco,1 Shaohua Li, 2 Gyan Bhanot,3 Bruce G Haffty, 1 Wenwei Hu,1,5 Zhaohui Feng,1,5 6 7 1 Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, The State 8 University of New Jersey, New Brunswick, NJ 08903, USA. 9 2 Department of Surgery, Robert Wood Johnson Medical School, Rutgers, The State University of 10 New Jersey, New Brunswick, NJ 08903, USA. 11 3 Department of Molecular Biology, Biochemistry & Physics, Rutgers, The State University of New 12 Jersey, Piscataway, NJ 08854, USA. 13 4 Co-first authors 14 5 Correspondence: W.H. (email: [email protected]) or Z.F. (email: [email protected]) 15 Running Title: GLS2 inhibits Rac1 to suppress metastasis 16 1 17 Abstract 18 Glutaminase (GLS) isoenzymes GLS1 and GLS2 are key enzymes for glutamine metabolism. 19 Interestingly, GLS1 and GLS2 display contrasting functions in tumorigenesis with elusive 20 mechanism; GLS1 promotes tumorigenesis, whereas GLS2 exhibits a tumor suppressive function. 21 In this study, we found that GLS2 but not GLS1 binds to small GTPase Rac1 and inhibits its 22 interaction with Rac1 activators guanine-nucleotide exchange factors (GEFs), which in turn inhibits 23 Rac1 to suppress cancer metastasis. This function of GLS2 is independent of GLS2 glutaminase 24 activity. Furthermore, decreased GLS2 expression is associated with enhanced metastasis in human 25 cancer.
    [Show full text]